Indraprastha Medical Corporation Limited (INDRAMEDCO) AI Stock Analysis

• Market Cap: ₹46.47B
• Dividend Yield: 0.88%
• Average Volume (3M): 33.92K
• Price to Earnings (P/E): 26.6
• Beta (1Y): 1.18
• Revenue Growth: 6.51%
• EPS Growth: 18.24%
• Country: IN
• Employees: 2,977
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 5.40
• Shares Outstanding: 91,673,000
• 10 Day Avg. Volume: 18,340
• 30 Day Avg. Volume: 33,918
• PEG Ratio: 0.75
• Price to Book (P/B): 6.04
• Price to Sales (P/S): 2.66
• P/FCF Ratio: 29.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 356.82
• Revenue Forecast (FY): ₹1.34T

• Rating: 69 Neutral
• Price Target: ₹608.00 ▲(18.59% Upside)

Indraprastha Medical Corporation Limited's overall stock score is driven by strong financial performance and positive technical indicators. However, the high P/E ratio suggests potential overvaluation, which tempers the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Profitability

Improving profit margins reflect operational efficiency and cost management, supporting sustainable profitability and shareholder value.

Low Leverage

Low leverage reduces financial risk and enhances the company's ability to invest in growth opportunities without excessive debt burden.

Negative Factors

Cash Reserves Decline

Declining cash reserves may limit financial flexibility and ability to respond to unexpected expenses or investment opportunities.

Operating Cash Flow Decline

Reduced operating cash flow could impact liquidity and the ability to fund operations, necessitating careful cash management.

Free Cash Flow Decline

Decreased free cash flow may constrain investment in growth initiatives and shareholder returns, affecting long-term growth prospects.

Indraprastha Medical Corporation Limited Business Overview & Revenue Model

Company Description

Indraprastha Medical Corporation Limited (INDRAMEDCO) is a prominent player in the healthcare sector, specializing in the manufacture and distribution of medical devices and equipment. The company offers a diverse range of products, including surgical instruments, diagnostic equipment, and hospital furniture, catering to both domestic and international markets. With a commitment to quality and innovation, INDRAMEDCO aims to enhance patient care through its state-of-the-art healthcare solutions.

How the Company Makes Money

INDRAMEDCO generates revenue through several key streams, primarily from the sale of its medical devices and equipment to hospitals, clinics, and healthcare providers. The company may also engage in contracts for supplying medical products to government and private healthcare institutions, which can provide a steady revenue source. Additionally, INDRAMEDCO could derive income from partnerships with other healthcare companies for co-development of products and distribution agreements that expand its market reach. The focus on expanding its product portfolio and entering new markets contributes significantly to its earnings.

Indraprastha Medical Corporation Limited Financial Statement Overview

Summary

Indraprastha Medical Corporation Limited shows strong financial health with consistent revenue growth and profitability. The balance sheet reflects low leverage and solid equity, though recent declines in cash reserves suggest a need for vigilant cash flow management.

Income Statement

Indraprastha Medical Corporation Limited has demonstrated strong revenue growth over the years, increasing from 5,960 million INR in 2021 to 13,563 million INR in 2025. The gross profit margin has improved significantly, indicating strong operational efficiency, and the net profit margin has also shown consistent improvement, reaching 11.87% in 2025. The EBIT and EBITDA margins reflect healthy profitability, contributing to a robust income statement performance.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio consistently low, indicating low leverage risk. Return on equity has improved, reflecting efficient use of equity capital. The equity ratio is strong, showing financial stability; however, the decrease in cash and cash equivalents from 2024 to 2025 indicates potential liquidity considerations.

Cash Flow

The cash flow statements reveal stable operational cash flows, though there was a decline in free cash flow in 2025 compared to the previous year. The free cash flow to net income ratio is healthy, suggesting effective cash generation relative to profit. However, the decline in operating cash flow in 2025 needs monitoring to ensure continued liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.74B	13.56B	12.45B	10.99B	8.88B	6.13B
Gross Profit	3.69B	3.50B	3.13B	6.25B	4.79B	3.47B
EBITDA	2.69B	2.44B	2.07B	1.61B	1.17B	409.48M
Net Income	1.68B	1.61B	1.24B	861.50M	586.20M	23.30M
Balance Sheet
Total Assets	0.00	8.52B	7.23B	5.55B	4.62B	4.32B
Cash, Cash Equivalents and Short-Term Investments	3.22B	3.19B	2.24B	1.36B	660.10M	296.10M
Total Debt	0.00	327.60M	339.50M	24.80M	53.10M	78.18M
Total Liabilities	-5.97B	2.55B	2.45B	1.76B	1.36B	1.59B
Stockholders Equity	5.97B	5.97B	4.78B	3.79B	3.25B	2.73B
Cash Flow
Free Cash Flow	0.00	1.20B	1.31B	998.90M	418.10M	69.35M
Operating Cash Flow	0.00	1.57B	2.00B	1.44B	712.90M	278.98M
Investing Cash Flow	0.00	-1.11B	-1.58B	-1.08B	-511.00M	-201.62M
Financing Cash Flow	0.00	-458.80M	-323.80M	-260.40M	-33.70M	-31.47M

Indraprastha Medical Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 512.70
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDRAMEDCO, the sentiment is Neutral. The current price of 512.7 is below the 20-day moving average (MA) of 555.91, below the 50-day MA of 529.63, and above the 200-day MA of 450.03, indicating a neutral trend. The MACD of -8.62 indicates Positive momentum. The RSI at 41.16 is Neutral, neither overbought nor oversold. The STOCH value of 11.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:INDRAMEDCO.

Indraprastha Medical Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INDRAMEDCO	69 Neutral	₹46.47B	26.60	―	0.88%	6.51%	18.24%
PFIZER	69 Neutral	₹233.87B	28.92	―	0.70%	6.13%	35.83%
BIOCON	63 Neutral	₹531.84B	100.38	―	0.13%	10.62%	-66.88%
GLAXO	63 Neutral	₹450.87B	47.45	―	2.17%	4.17%	41.51%
CONCORDBIO	61 Neutral	₹152.42B	42.80	―	0.76%	3.63%	-1.21%
METROPOLIS	61 Neutral	₹105.27B	68.82	―	0.20%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%